Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 71 pages | ID: G378C8CF2957EN
Global Markets Direct

Abstracts

Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

The report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 2, 1, 8, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Other Diseases and Undisclosed which include indications Short Bowel Syndrome, Graft Versus Host Disease (GVHD), Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Osteoporosis, Unspecified and Unspecified Metabolic Disorders.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
• The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 9 Meters Biopharma Inc, 2022
Pipeline by Amogen Pharma Pvt Ltd, 2022
Pipeline by Applied Molecular Transport Inc, 2022
Pipeline by Bainan Biotech ApS, 2022
Pipeline by Entera Bio Ltd, 2022
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Pipeline by Huons Global Co Ltd, 2022
Pipeline by OPKO Health Inc, 2022
Pipeline by Peg-Bio BioPharma Co Ltd, 2022
Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Pipeline by Sosei Group Corp, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
Pipeline by VectivBio Holding AG, 2022
Pipeline by Zealand Pharma AS, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022